An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities

被引：21
|
作者：
Agarwal, Sheetal [1 ]
Chinn, Leslie [1 ]
Zhang, Lei [1 ]
机构：
[1] US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
来源：
PHARMACEUTICAL RESEARCH | 2013年 / 30卷 / 03期
关键词：
drug-drug interaction; labeling; package insert; regulatory; transporter;
D O I：
10.1007/s11095-012-0924-0
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：899 / 910
页数：12
相关论文
共 47 条
  • [21] Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019
    Ramamoorthy, Anuradha
    Kim, Hannah H.
    Shah-Williams, Ebony
    Zhang, Lei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (04): : 486 - 493
  • [22] IMPACT OF POPULATION PHARMACOKINETIC ANALYSES ON LABELING: A REVIEW OF NEW MOLECULAR ENTITIES LABELS APPROVED BETWEEN 2011 AND 2015
    Wu, Y. S.
    Bhattaram, A.
    Earp, J.
    Florian, J.
    Grillo, J.
    Krudys, K.
    Lee, J.
    Li, F.
    Li, H.
    Liu, C.
    Liu, J.
    Ma, L.
    Marathe, A.
    Marathe, D.
    Mulugeta, Y.
    Rekic, D.
    Wang, X.
    Wang, Y.
    Xu, Y.
    Yang, Y.
    Younis, I.
    Yu, J.
    Zhao, P.
    Zheng, N.
    Zhuang, L.
    Sinha, V.
    Mehrotra, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S91 - S91
  • [23] New molecular entities/new biologics - Xolair - Omalizumab - Genetech/Novartis/Tanox - First biologic approved for the treatment of allergic asthma
    不详
    FORMULARY, 2003, 38 (07) : 392 - +
  • [24] Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999
    Cross, J
    Lee, H
    Westelinck, A
    Nelson, J
    Grudzinskas, C
    Peck, C
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (06) : 439 - 446
  • [25] In vivo drug-drug interaction studies - A survey of all new molecular entities approved from 1987 to 1997
    Marroum, PJ
    Uppoor, RS
    Parmelee, T
    Ajayi, F
    Burnett, A
    Yuan, R
    Svadjian, R
    Lesko, LJ
    Balian, JD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (03) : 280 - 285
  • [26] Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
    Hui-Heng Lin
    Le-Le Zhang
    Ru Yan
    Jin-Jian Lu
    Yuanjia Hu
    Scientific Reports, 7
  • [27] Racial/Ethnic Composition of Study Participants in FDA-Approved Oncology New Molecular Entities, 2006-2008
    Merenda, Christine
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2012, 104 (9-10) : 430 - 435
  • [28] REVIEW OF RACIAL/ETHNIC DIFFERENCES IN PHARMACOKINETICS, PHARMACOGENOMICS, SAFETY, AND EFFICACY OF NEW MOLECULAR ENTITIES APPROVED BETWEEN 2014 AND 2018.
    Ramamoorthy, A.
    Shah-Williams, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S34 - S35
  • [29] Gender and Ethnicity of Enrolled Participants in US Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities
    Birnbaum, Faith A.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2018, 110 (05) : 473 - 479
  • [30] Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
    Lin, Hui-Heng
    Zhang, Le-Le
    Yan, Ru
    Lu, Jin-Jian
    Hu, Yuanjia
    SCIENTIFIC REPORTS, 2017, 7
12345